Francois Cedric
Chief Executive Officer
Francois Cedric has filed 8 SEC Form 4 filings (45 transaction rows) across 1 company, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: May 14, 2026.
On the most recent filing, Francois Cedric is listed as Chief Executive Officer at Apellis Pharmaceuticals, Inc. Inside the rolling window, Francois Cedric reported no open-market purchases and 3 open-market sales totaling $980K in APLS. The largest disclosed transaction in the window is a sale of 27,192 APLS shares on Jan 22, 2026, worth $592K.
Companies traded
Other insiders at APLS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$980K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
Frequently asked questions
How many SEC Form 4 filings has Francois Cedric made?
Francois Cedric has filed 8 SEC Form 4 filings (45 transaction rows) across 1 company since 2025.
Which companies does Francois Cedric trade?
Francois Cedric has filed SEC Form 4 disclosures for 1 company, including APLS.
When was Francois Cedric's most recent SEC Form 4 filing?
Francois Cedric's most recent SEC Form 4 filing on Tracefour is dated May 14, 2026.
What is Francois Cedric's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Francois Cedric is listed as Chief Executive Officer.
What is Francois Cedric's total buy and sell value in the current window?
Inside the rolling retention window, Francois Cedric bought $0 and sold $980K based on SEC Form 4 filings.
What was Francois Cedric's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 27,192 APLS shares on 2026-01-22, worth $592K, per SEC Form 4 filings.